Trimethoprim-sulfamethoxazole (TMP-SMX) for Pneumocystis jirovecii pneumonia (PCP) prophylaxis in combination with methotrexate (MTX) was shown to be successful and well-tolerated in patients with chronic inflammatory/autoimmune diseases.
Merck announced results from the phase 3 RESTORE-IMI 2 trial of imipenem/relebactam/cilastatin (Recarbrio™) for the treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP).
Data gathered from a meta-analysis of clinical practice guidelines published in the European Journal of Clinical Microbiology and Infectious Diseases, show that well-designed randomized controlled trials are urgently needed.
Exposure to carbapenem and carboxypenicillin or ureidopenicillin during the week before onset of ventilator-associated pneumonia and the severity of disease with regard to respiratory and hematologic failures were independent risk factors for the occurrence of Stenotrophomonas maltophilia-related VAP.
The objective surveillance for nonventilator hospital-acquired pneumonia (HAP) via electronically computable definitions generates incidence, mortality, and adjusted odds ratios [OR] for hospital mortality similar to those generated by manual surveillance.
The decision to update the pneumococcal vaccine recommendations was based on a review of evidence that demonstrated that the implementation of the 2014 recommendation had minimal impact on PCV13-type disease at the population level among older adults.